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Abstract
Extracellular vesicles such as exosomes, microvesicles, apoptotic bodies, and large oncosomes have been shown to
participate in a wide variety of biological processes and are currently under intense investigation in many different
fields of biomedicine. One of the key features of extracellular vesicles is that they have relatively large surface
compared to their volume. Some extracellular vesicle surface molecules are shared with those of the plasma membrane
of the releasing cell, while other molecules are characteristic for extracellular vesicular surfaces. Besides proteins,
lipids, glycans, and nucleic acids are also players of extracellular vesicle surface interactions. Being secreted and
present in high number in biological samples, collectively extracellular vesicles represent a uniquely large interactive
surface area which can establish contacts both with cells and with molecules in the extracellular microenvironment.
Here, we provide a brief overview of known components of the extracellular vesicle surface interactome and highlight
some already established roles of the extracellular vesicle surface interactions in different biological processes in health
and disease.
Keywords Extracellular vesicle . Surface . Interactome . Extracellular matrix . Drug delivery
Introduction
Extracellular vesicles (EVs) are membrane-enclosed het-
erogeneous structures that are secreted by all cells [1]
and have many different physiological and pathophysio-
logical roles [2]. They include small EVs of endosomal
origin (exosomes) as well as plasma membrane-derived
intermediate-sized (100–1000 nm) microvesicles, and
large sized (> 1 μm) apoptotic bodies and large
oncosomes [3, 4]. In the past few years, EVs attracted
rapidly growing scientific interest from various fields of
biomedicine.
Surface molecules of EVs are of critical functional signif-
icance as they (i) establish connections with the surrounding
micro milieu and with cells, (ii) determine EV mobility, (iii)
mediate cellular uptake, (iv) affect immune recognition of
EVs (also via posttranslational modifications) by the innate
and adaptive immune systems, and (v) may represent effector
molecules (such as FasL). On the other hand, from a re-
searcher’s perspective, they enable identification, affinity iso-
lation, and molecular classification of EVs and EV subtypes,
and enable the use of EVs as biomarkers.
Here, we overview EV surface interactions with the sur-
roundingmicroenvironment (extracellular matrix (ECM)mol-
ecules or components of the blood plasma) and with cells and
provide examples for the functional relevance of the surface
interactions of EVs.
Evidences for exofacial localization of EV
proteins as partners in EV surface interactions
When considering EV surface interactions, it is of crucial im-
portance to define EV molecules with exofacial topology that
can serve as interaction partners. EV surface molecules are
identified by immunolabeling (immunogold electron micros-
copy, flow cytometry or immunochemistry using confocal or
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super resolution microscopy). These widely used approaches
enabled identification of Bcanonical^ EV surface proteins in-
cluding tetraspanins (CD9, CD63, and CD81), integrins
(ITG), cell adhesion molecules (CAM), and growth factor re-
ceptors [5]. The presence of these molecules has been con-
firmed by many different laboratories.
Mass spectrometry (MS)-based proteomic characterization
has proven to be a very efficient and widely used tool to
characterize EVs. This approach was first used by Thery
et al. [6] for the characterization of exosomes followed by
many other studies over the years. These proteomic data are
also publicly available from databases (Exocarta, EVpedia,
and Vesiclepedia) (http://student4.postech.ac.kr/evpedia2_xe/
xe/, http://www.exocarta.org/, http://www.microvesicles.
org/). However, MS does not enable identification of the
precise topology of EV proteins. Possible membrane defects
due to centrifuge-based EV isolation procedures or the occur-
rence of inverted vesicles may enable labeled antibodies to
recognize internal cargo molecules of EVs making the distinc-
tion between EV surfaces and internal cargo proteins chal-
lenging. This possibility cannot be completely excluded even
when using, e.g., antibody-coated EVarrays [7].
Recently, a combination of proteinase treatment and sub-
sequent biotinylation, a strategy known from studying cellular
membrane proteins, has been suggested for the study of lumi-
nal and surface-accessible EV cargo [8]. Even with this ap-
proach, it cannot be determined whether the surface-
accessible EV proteins were present already at the time of
EV production or they were subsequently acquired from con-
ditioned media or biological fluids.
Strong evidence for EV surface localization of certain mol-
ecules comes from the ability to target the putative protein (or
other molecule) for affinity isolation of EVs. Anti-EpCAM
and anti-A33 antibodies were used for immunocapture of co-
lon cancer-derived exosomes [9]. Similarly, anti-tetraspanin
(antiCD63, CD9 and CD81) antibodies can be used for
immunoisolation of EVs [3]. Immune electron microscopy
revealed that hsp70 is localized on the surface of exosomes
[10], and a synthetic peptide (Vn96) with high affinity for heat
shock proteins has proven useful for affinity enrichment of
cancer EVs [11–13]. Furthermore, EVs can be isolated by
heparin affinity purification. Suggested heparin-binding pro-
teins on EVs include histones, heat shock proteins, and
annexin; however, definite interacting ligand(s) have not been
determined yet [14]. Of note, not only proteins but also other
surface molecules are targeted for EV affinity capture. As an
example, the recently identified phosphatidyl serine (PS) re-
ceptor TIM4 [15] was found efficient in capturing PS-
exposing EVs [16].
For immunodetection of EV surface molecules, dot scan
(antibody microarray) has been used recently. It showed
moderate/high levels of CD19, CD5, CD31, CD44, CD55,
CD62Lm, CD82, HLA-A, B, and C and low levels of
CD21, CD49c, and CD63 on EVs. The authors proposed
these EV surface molecules as a diagnostic signature for
chronic lymphocytic leukemia [17]. Furthermore, surface
plasmon resonance (SPR) has been used recently for the si-
multaneous detection of both EV and cancer markers on
exosomes from breast cancer cells [18]. Moreover, exosome
Bsurfaceome^ profiling was carried out by an initial MS test-
ing EVs secreted by 13 pancreatic ductal adenocarcinoma cell
lines and 2 non-neoplastic cell lines. MS was followed by
identification of candidate biomarkers and validation by an
immunocapture pulldown assay. In this assay, a multiplexed
panel of antibodies was used that included anti-CLDN4,
EPCAM, CD151, LGALS3BP, HIST2H2BE, and
HIST2H2BF antibodies for the enrichment of tumor-specific
exosomes for subsequent studies [19].
Numerous pieces of evidence suggest that surface mole-
cules on EVs determine the uptake and biological functions
of EVs. As one example, blockade of exosome surface SIRPα
(CD47) was shown to be effective in increasing cancer cell
phagocytosis [20].
Interaction of EVs with the plasma membrane
of cells
Surface interactions of EVs with the plasma membrane are of
outstanding importance since such interactions mediate bind-
ing of EVs to cells resulting in signal transduction or uptake of
EVs by cells. It is now established that EV-target cell interac-
tions involve tetraspanins, integrins, ECM proteins, immuno-
globulin superfamily members, proteoglycans, and lectins [21,
22]. Details of EV docking and entry to cells are not in the
focus of this review, as these interactions have recently been
reviewed elsewhere [21, 22]. To illustrate the outstanding
functional significance of the interaction of EV surface mole-
cules with those of the plasma membrane, here, we only refer
to the plethora of EV-immune cell interactions including cell-
free antigen presentation by EVs [23], Fas ligand or TRAIL-
mediated cell death induction by EVs [24–26], or the transfer
of immune checkpoint molecules (PD1, PDL-1) by EVs [27].
Here, we also point out the significance of externalization
(translocation to the outer leaflet of a phospholipid bilayer) of
phosphatidyl serine (PS), a characteristic feature of many
EVs. The negatively charged, surface-exposed phospholipid
PS is recognized by numerous plasma membrane receptors
either directly or indirectly, via bridging proteins. Direct PS
sensing receptors include the previously mentioned TIM4
[15], the receptor for advanced glycation end products,
RAGE [28], brain-specific angiogenesis inhibitor 1 Bai-1
[29], and stabilin-2 [30]. Indirect PS recognition and subse-
quent uptake is mediated by milk fat globule-EGF factor
8, MFGE8 [31] which forms a molecular bridge between
PS and plasma membrane integrins (such as αvβ3) [31]
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(Fig. 1a).Of note, MFGE8 is not only detectable on the
surface of exosomes [32], but it is also secreted by cells as
an EV-MFGE8 complex [33]. This EV-protein complex
secretion is similar to secretion EV-integrin-FN and EV-
C3b complexes (Fig. 1b).
Of note, similar indirect recognition of PS is also described
in the case of PS recognized by the growth arrest-specific
protein 6, Gas6. The PS-Gas6 complex was shown to activate
TAM family member MER tyrosine kinases on the surface of
macrophages triggering uptake and inducing an anti-
inflammatory phenotype [34].
Until now, most studies investigated PS–plasma membrane
receptor interactions focusing on the uptake of apoptotic cell-
derived vesicles. This is explained by the fact that apoptosis
has been long known to be accompanied by PS externalization.
However, given that externalized PS is characteristic for many
EV surfaces, and annexin V is used broadly to detect EVs, it
seems plausible that PS-mediated interactions with the plasma
membrane govern the binding and uptake of non-apoptotic
EVs as well. Indeed, there are accumulating pieces of evidence
that show PS-mediated EV uptake or signaling in the case of
non-apoptotic vesicles also [35, 36].
Interaction of EV surfaces
with the extracellular matrix: extracellular
binding or re-cycling?
It is an important question whether EVs secreted by cells of
tissues rich in extracellular matrix (ECM) such as connective
Fig. 1 Examples for EV surface interactions with the plasma membrane
and components of the extracellular matrix. a One of the best
characterized interactions between the plasma membrane and the
surface of EVs is mediated by proteins that recognize externalized
phosphatidyl serine (PS) on EVs. Direct interactions with PS include
those with TIM4, stabilin-2, RAGE, or BAI-1. Indirect interactions in-
clude those between the PS-binding MFGE-8 and αvβ3 integrin as well
as the PS-binder GAS-6 and the MER tyrosine kinase on the cell. b
Endocytosis of fibronectin (FN) or C3b complement protein is followed
by an association of these molecules with intraluminal vesicles within
MVBs followed by secretion of exosomes with surface-associated FN
or C3b. c Interaction of EVs with ECM is mediated by integrins or
CD44. d FN forms a bridge between HSPGs present on both EV surface
and plasma membrane, and mediates EV uptake by cells
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tissue, interact with matrix molecules. Accumulating pieces of
evidence suggest that indeed such interactions exist and their
significance is increasingly recognized. It may seem intuitive
that EV surfaces interact with the ECM components upon
secretion, once being surrounded by the macromolecular
ECM milieu. This may predict that EV membrane deposition
of matrix molecules results from binding of these molecules
onto EV surfaces extracellularly. Although newly secreted
EVs evidently establish interactions with ECM molecules in
tissues and body fluids (Fig. 1c), there seems to be another
mechanism, which may explain the presence of certain ECM
molecules on the surface of EVs. It has been proposed recently
that cells endocytose ECM molecules and re-secrete them on
the exofacial surface of EVs (exosomes) [37] (Fig. 1b). This
continuous endocytosis and re-secretion of ECM components
guarantees an abundant source of ECM-carrying EVs, which
may play an important role in cell migration. Such endocyto-
sis and EV-associated re-secretions has been recently demon-
strated in the case of fibronectin (FN)–integrin complexes. FN
is endocytosed in association with integrins, it is then targeted
to MVB, where it binds to the surface of intraluminal vesicles
in correct topology to interact with both the cell surface and
other ECM molecules (e.g. collagen fibers) [37].
Kowal et al. used immuno-isolated EVs by CD9, CD63,
and CD81-specific antibodies. The authors have demonstrated
the existence of a subtype of small EVs (sEVs) that the authors
referred to as Bdense sEVs^ which carried FN, complement,
prothrombin, and serum albumin, while another subpopula-
tion of sEVs (Blight sEVs^) did not carry any of these mole-
cules on its surface [3]. Whether dense sEVs acquired their
ECM coat from the conditioned medium of the cells upon
secretion or were secreted with surface-bound ECM mole-
cules, was not investigated in this study.
Fibronectin
One of the most extensively studied ECM molecules with
respect to surface interaction with EVs is FN. FN binds mul-
tiple integrins. It has been shown that reticulocyte maturation
is accompanied by release of EVs carrying α4β1 integrin
(Very Late Antigen-4, VLA4) by which EVs were shown to
bind to FN [38]. Myeloma-derived EVs (exosomes) were
found to carry FN on their surface [39]. This exofacially
bound FN could interact with cell surface heparan sulfate
(through its Hep-II domain). The authors showed that FN
could simultaneously bind to heparan sulfate proteoglycans
both on the exosomal and the plasma membrane surfaces
thereby facilitating cellular uptake of EVs [39] (Fig. 1d).
There are multiple evidences that beyond facilitating cell
binding and cellular uptake, there are other functional conse-
quences of EV-association of FN. A striking function of FN
on EVs is related to cellular motility. As described above, FN
bound to integrins on exosomes was shown to promote direc-
tional cancer cell movement by reinforcing transient polariza-
tion states and adhesion assembly [37]. Furthermore,
exosomal FN was shown to induce IL-1β expression by mac-
rophages [40]. We have shown recently that DNA present on
the surface of small EVs secreted by stressed cells facilitated
interaction of EVs with FN [41]. Finally, FN on circulating
EVs in liquid biopsy samples of breast cancer patients samples
was suggested to be a promising cancer biomarker [42].
Glycosaminoglycans (GAGs)
and proteoglycans
Heparan sulfate proteoglycans (HSPGs) are abundant glyco-
proteins having a core protein to which one or more heparan
sulfate (HS) glycosaminoglycan (GAG) chains are attached
covalently. Membrane-bound HSPGs include syndecans and
glypicans. Interestingly, syndecans and glypicans are present
both on the plasma membrane of the EV-releasing cells and
the membrane of EVs. Cancer cell-surface HSPGs of the
syndecan and glypican types were shown to mediate internal-
ization of EVs [43]. This process was readily inhibited by free
heparan sulfate. Importantly, the same study demonstrated
sorting of HSPGs to EVs (exosomes) [43]. As we mentioned
earlier, by forming a bridge between EV and plasma mem-
brane HSPGs, FN was shown to mediate EV uptake [39].
Recently, the presence of glypican 1 associated with
exosomes was demonstrated by different groups [44–46]. Its
proposed exploitation as a biomarker of pancreatic cancer is
currently under investigation.
Among other ECM molecules, hyaluronan (HA) synthesis
was shown to be associated with the shedding of HA-coated
EVs by human mesenchymal stem cells (Fig. 1d). HA coating
on EVs was proposed to (i) contribute to HA-mediated tissue
regeneration, (ii) regulate interactions of EVs with target cells,
and (iii) play a role in ECM remodeling [47]. Not only HA but
also the HA receptor CD44 is associated with EV surfaces.
Ovarian cancer cell invasion was shown to be supported by
exosomal transfer of CD44 to peritoneal mesothelial cells
[48]. CD44 was also identified as a component of the cancer
cell-derived circulating EV-specific diagnostic signature [17]
and was recently shown to serve as one of the diagnostic and
prognostic exosomal biomarkers of breast cancer [49].
Interestingly, transcripts of CD44 are also carried horizontally
as internal cargo in human mesenchymal stem cell-derived
HA-coated EVs [47].
The role of integrins in EV-ECM interactions
Integrins represent a group of transmembrane receptors that
play a role in cell-ECM adhesion. Known integrin ligands in
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the ECM include molecules such as fibronectin, collagen,
vitronectin, and laminin. Numerous pieces of evidence sup-
port that among EV surface adhesion molecules, integrins
play a distinguished role. Tumor EVs (exosomes) can promote
cancer progression by transferring integrin transcripts hori-
zontally and by selecting metastatic sites as reviewed recently
[50]. Tumor-derived EV (exosome) integrins α6β4 and α6β1
correlated with the development of lung metastasis, while
exosomal integrin αvβ5 was associated with liver metastasis
[51]. This important observation suggests that there is a po-
tential of EVs to predict metastatic sites of tumors based on
their surface integrins.
EVs and the blood plasma
Immunoglobulins
The association of EVs with plasma factors, notably immuno-
globulins and complement factors (Fig. 2a, b), is best de-
scribed concerning the spectrum of autoimmune rheumatolog-
ical diseases. Systemic lupus erythematosus (SLE) and rheu-
matoid arthritis (RA) are autoimmune diseases with a signif-
icant type III hypersensitivity component meaning that im-
mune complexes and complement activation contribute to
the disease pathology.
EVs have been known to associate with autoantibodies in
several autoimmune diseases, forming pro-inflammatory im-
mune complexes contributing to disease pathology as we
reviewed recently [52]. In RA synovial fluid, platelet EVs
display autoantigens and form immune complexes, which po-
tently activate neutrophils thereby perpetuating inflammation
[53]. SLE is an immune complex disease where disease symp-
toms arise due to the reduced clearance of immune complexes,
which leads to complement-mediated inflammation. EVs also
associate with immunoglobulins and enhance the formation of
such pathological immune complexes in SLE [54]. A recent
study showed that distinct subpopulations of EVs harboring
immunoglobulins were associated with distinct clinical char-
acteristics of SLE and may therefore serve as biomarkers in
future [55].
Autoimmune phenomena can also arise due to autoanti-
bodies produced against nucleic acids. EV-associated chroma-
tin is normally digested off by DNAse1L3. The loss of this
mechanism can lead to the formation of autoantibodies which
in turn can cause autoimmunity [56].
Complement
It was demonstrated that complement activation occurs on
platelet-derived microvesicles (also referred to as microparti-
cles). Complement proteins (C3b and C5b-9) were shown to
deposit on the surface of platelet-derived EVs exposed to
blood plasma. Of note, not only complement proteins but also
complement regulatory proteins (C1-INH, CD55, and CD59)
were present on platelet EVs. The authors proposed that these
EVs may present concentrated activated complement compo-
nents to targets in the blood vessels [57].
Complement components have a major role in the clear-
ance of apoptotic cells. In SLE, the mechanism of apoptotic
cell clearance is damaged which leads to the disease symp-
toms of widespread inflammation due to chronic complement
activation. Complement components associated with EVs and
an altered binding of C3 components to EVs were observed in
SLE even though there was no difference in the concentration
of EVs between SLE patients and healthy subjects. SLE pa-
tients had higher levels of C3d-positive EVs and lower levels
of C3b and C3ib-positive EVs. Since the latter components
opsonize cells and EVs for phagocytosis, this difference could
also contribute to chronic inflammation [58]. Association of
complement factors with EVs in different types of renal dis-
ease has been extensively reviewed in [59].
It appears that in autoimmune and renal diseases, binding
of different complement factors to EVs is preferential.
Similarly, the attachment of complement factors, immuno-
globulins, and other serum components to artificial particles
depends on the particles’ surface chemistry. Differential bind-
ing of such plasma components has an influence on the adju-
vant properties of the particles and thus has an influence on the
use of these particles in vaccine delivery. Importantly, com-
plement factors were necessary for the uptake of the artificial
particles by antigen presenting cells via complement receptor
3 in mice [60].
EV-associated complement proteins may not only directly
attach onto EVs upon exposure to blood plasma. C3 fragments
were detected by immune electron microscopy in MVBs on
the surface of intraluminal vesicles [60]. This may represent
another example for endocytic uptake and exosomal re-
secretion of an extracellular protein. These C3b-coated EVs
were suggested to have an immunomodulatory role by en-
hancing the antigen presentation [60] (Fig. 2b).
Association of coagulation factors with EVs
Early evidence for procoagulant surfaces in platelet-free blood
plasma was published by Wolf and collegues and was de-
scribed as Bplatelet dust^ back in 1967 [61]. Since then, a
high number of studies confirmed that platelet-derived
EVs, highly abundant in blood plasma, indeed have
procoagulant properties. Furthermore, non-platelet EVs
such as tumor derived vesicles [62] proved to affect he-
mostasis partially by assembling factors of coagulation on
their surface in the blood plasma. The most extensively
studied two components of EVs in coagulation are
phosphatidylserine (PS) and tissue factor (TF) (Fig. 2c).
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As a high percentage of platelet-derived MVs bear the an-
ionic phospholipid PS on their outer membrane, they facilitate
the assembly of several proteins of the coagulation cascade.
These proteins contain positively charged γ-carboxyglutamic
acid domains to which PS can bind with electrostatic interac-
tion. These factors include VII, IX, X, and prothrombin [63].
Underlining the importance of PS-positive EV formation in
hemostasis, patients suffering from a rare bleeding disorder
(Scott syndrome) were found to have reduced floppase activ-
ity resulting in faulty PS externalization and reduced micro-
particle shedding [64].
Also, TF, a transmembrane receptor of factor VII/VIIa, can
be present on MVs (vesicles often referred to as microparti-
cles, MPs in coagulation studies). The elevated activity levels
of this protein have been detected in various diseases (such as
in acute liver injury, cirrhosis, urinary tract infection,
endotoxemia, influenza, cancer, and related thromboembo-
lism [65]). The platelet origin of TF on platelet MVs and the
overall relevance of TF-bearing platelet MVs have been
questioned by several authors [66–68]. However, the role of
TF positive EVs irrespective whether they originate form
platelets, tumor cells, endothelial cells, or leukocytes is clear
in various hemostatic diseases and diseases tipically present-
ing with thrombembolic complications (as detailed in the
comprehensive review by Owens and Mackman [63]). The
presence of TF on EVs makes the presence of its specific
inhibitor molecule, tissue factor pathway inhibitor (TFPI), al-
so probable [63].
In addition to assembling factors that initiate the coagula-
tion cascade, platelets and their MPs also can present specific
binding sites for factors V, IX, and VIII [69–71]. Indeed, these
binding sites can be found concentrated on MPs relative to
platelets. In the case of factor Va and VIIIa, a 10-fold, while in
the case of factor IXa, a 2-fold concentration of factor binding
sites was observed in the above mentioned studies [69–71].
Another factor, von Willebrand Factor (vWF), an interaction
partner of both glycoproteins GPIb and GPIIbIIIa, was found
to be attached to platelet- and also to endothelial cell-derived
EVs [72, 73]. Together, the accumulation of PS and of other
coagulation factor binding sites enables the surface of platelet
MPs to enhance coagulation approximately 50–100-fold as
compared to platelets [74].
Interestingly, depending on what stimuli the parent cell
recieved, MPs may bear different surface molecules resulting
Fig. 2 Examples for EV surface-associated molecules. a Antibody bind-
ing to EVs has been demonstrated, e.g., in numerous autoimmune dis-
eases. b Both complement factors and complement regulatory proteins
have been shown to associate with EV surfaces. c On EVs from blood
plasma, different coagulation factors are also identified. d EV-associated
cytokines include TNF bound to TNF receptor as well as TGFβ bound to
TGFβR3 (betaglycan) on EV surfaces. e Both bacterial and mammalian
EVs have been demonstrated to carry surface-associated DNA and DNA-
binding proteins. In the case of mammalian EVs, both mitochondrial and
nuclear DNAwere found on EV surfaces. fA surprisingly large variety of
EV surface enzymes were identified that can bind and cleave protein or
glycan substrates of the EV microenvironment
458 Semin Immunopathol (2018) 40:453–464
in different binding features. For instance, platelets activated
with thrombin or collagen were found to shed MPs exposing
GPIIbIIIa complexes binding fibrinogen, while those activat-
ed with C5b-9 shed non-GPIIbIIIa-exposing MPs [70].
Although the effect of platelet-derived microvesicles has
been studied most widely, it is important to note that activated
platelets also secrete exosomes [75]. However, their associa-
tion with coagulation factors in plasma is questionable, as
they, if at all, bear very low levels of PS [76]. Also, it is
controversial whether plasma exosomes of different cellular
origin bear TF [77].
Association of EVs with lipoproteins
Isolation of EVs from human blood plasma or serum is often
confounded by the co-isolated lipoproteins [78–81].
Moreover, antibody-mediated depletion of lipoproteins [82]
and lipoprotein apheresis [83] both resulted in loss of EV
content as well. On the other hand, MS analysis of VLDL
and LDL particles purified from human blood plasma re-
vealed the presence of EV proteins (CD14, LDL-receptor,
HLA class I molecules, and protein S100-A8) in these isolates
[84]. Taken together, these data suggest that beyond the shared
physiological parameters, there might be an association be-
tween lipoproteins and EVs as well. In vitro association
has already been demonstrated by transmission electron
microscopy [80]. However, experimental data are not
available yet in support of an in vivo association of EVs
and lipoproteins. Exchange of the protein and lipid con-
tent between lipoproteins is an established phenomenon
[85–88]. Exchange of ApoE between lipoproteins and
hepatitis C virus lipoviral particles has been also de-
scribed [89]. Moreover, in vitro SR-B1-dependent transfer
of a fluorescent phospholipid from engineered HDL nano-
particles to exosomes was also reported [90]. Finally,
ApoE has been implicated in amyloid formation of pig-
ment cells [91], and it has been shown that in these cells,
ApoE associates with intraluminal vesicles and is secreted
on the surface of exosomes [92].
Further blood plasma proteins associated
with the surface of circulating EVs
Beside the known role of EVs as carriers of luminal cargo,
EVs may also carry a significant surface cargo. Technically
challenging to investigate, so far, very little is known about the
externally adsorbed proteins. It is likely that the external cargo
of EVs is at least partly acquired in body liquids after the EVs
have been shed. As an example, blood plasma-derived EVs
commonly carry substantial amounts of albumin [93]. In line
with this, proteomics data in EV databases (http://student4.
postech.ac.kr/evpedia2_xe/xe/, http://www.exocarta.org/,
http://www.microvesicles.org/), [94–96] show that blood
plasma-derived EVs co-isolate with numerous blood plasma
proteins. Given the known presence of integrins and HSPGs
on EVs, integrin ligands and heparin binding proteins are
evident potential partners to establish interactions on the sur-
face of circulating EVs. Furthermore, phosphatidyl serine
binding proteins (such as MFGE8) and glycan binding
galectins are obvious interaction partners of EVs in the circu-
lation. Systemic analysis of EVs surface interactions with
blood plasma proteins is still lacking.
Association of EVs with cytokines/chemokines
An increasing number of data support that EVs are capable of
carrying various cytokines [2]. In most instances, these cyto-
kines are carried in EVs as part of the internal cargo. However,
it was shown that EVs carry a full-length 55-kDa tumor ne-
crosis factor receptor 1 (TNFR1). Importantly, it was demon-
strated by the authors that HUVEC-derived exosomes carried
bound TNF [97] (Fig. 2d).
In addition, TGF beta was shown to be associated
with the cell-surface chondroitin sulfate/heparan sulfate
proteoglycan betaglycan (also referred to as transforming
growth factor beta receptor III, TGFBR3) on the surface
of cancer cell-derived exosomes. Although the authors
found that the kinetics and magnitude of biological re-
sponse were similar irrespective if they used soluble or
EV-associated TGF beta, there were some qualitative dif-
ferences in the elicited cellular responses [98] (Fig. 2d).
Although it is tempting to hypothesize that additional
cytokines (including chemokines) may be carried on the
surface of EVs in association with EV surface proteogly-
cans, a systemic analysis of this question has not been
performed yet.
DNA associated with the surfaces of EVs
In bacteria, outer membrane vesicle (OMV)-associated DNA
has been shown to mediate inter- and intra-species horizontal
gene transfer by carrying antibiotic resistance genes and viru-
lence factor [99–101], and participating in the establishment
of bacterial biofilms [102, 103]. Recently, it was also reported
that OMV-associated DNA was found predominantly on the
outer surface of OMVs [104].
In mammalian systems, most studies so far focused on
DNA encapsulated in EVs as an internal cargo, and only very
few reports investigated the EV surface-associated DNase-
sensitive DNA. Of note, these studies drew attention towards
the potential of EV surface-associatedDNA in horizontal gene
transfer [105], induction of autoimmunity [56], and cellular
uptake [106]. Recently, we have shown that antibiotic-
exposed cells undergoing genotoxic shock secreted small
EVs (exosomes) with surface-associated DNAwhich was pre-
dominantly mitochondrial DNA [41]. The amount of this
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DNAwas not enhanced by induction of apoptosis of the EV-
releasing cells. As mentioned earlier, exosome surface-
associated DNAwas capable of mediating EV binding to FN
[41] (Fig. 2e).
Enzymes associated with EV surfaces
Several pieces of evidence support the presence and activity of
EV-associated enzymes as reviewed recently [107]. Thus, en-
zymes do not only represent components of the EV internal
cargo but are also characterized by active exofacial enzymes.
These include both proteases MT1-MMP (MMP-14) [108],
ADAM17 [109], insulin-degrading enzyme (IDE) (insulin-
like), and EV surface-associated glycosidases such as
sialidase NEU3 [110, 111] and heparanase [112].
Importantly, EV surface-associated proteases and glycosi-
dases may exert their function in concert with one another in
matrix degradation. In addition, flow cytometry of isolated
EVs bound to latex beads demonstrated the presence of mul-
tiple other enzymes (MMPs-2, -3, -9, -13, -14, ADAM-10,
ADAM-17, ADAMTS-5, ADAMTS-8, uPAR, and hyaluron-
idase) [113]. EV-associated enzymes may (i) facilitate cell and
EV mobility by degrading ECM macromolecules as sub-
strates, (ii) release bound growth factors or chemokines, and
(iii) destruct amyloid β plaques [114] (Fig. 2f).
EV surface-associated thiols
Thiol interactions are relevant both in the release and uptake
of EVs, and it is highly likely that the content and composition
of exofacial thiols has a vast influence on the interactions of
EVs with their environment including macromolecules. The
total surface thiol content of EVs can also be utilized for la-
beling purposes [115]. Plasma-derived and tissue culture-
derived EVs can equally be labeled by thiol-reactive fluores-
cent reagents. However, it is important to be aware that con-
taminating plasma proteins interfere with such labeling and
therefore, a dual labeling protocol of EV thiols is preferable
from plasma samples [115]. Certain plasma proteins, like al-
bumin, have a reactive thiol moiety [116], and interactions
with EVs may take place via thiol interactions. In particular,
in the case of albumin, it seems feasible that EVs form part of
the Balbuminome^ potentially extending their half-life in the
circulation via interacting with albumin. Albumin certainly
appears among the molecules associated with EVs as
discussed above. Redox regulation of cellular surface mole-
cules is an emerging factor affecting cellular functions.
Importantly, adhesion molecules such as integrins underlie
redox regulation. Reducing the α4-integrin by N-acetyl-cys-
teine leads to increased FN adhesion and cellular aggregation
of Jurkat cells [117]. Similar redox regulation may be relevant
in EV biology. EV-associated integrin regulation is of partic-
ular interest, since distinct expression pattern of integrins on
EVs is responsible for organotropism in cancer metastasis
[51]. Therefore, redox regulation of exofacial molecules on
EVs is likely to affect their functions.
Several thiol-reactive antioxidants are present in the plas-
ma, notably certain members of the thioredoxin family such as
peroxiredoxins 1, 2, and 4 and different forms of thioredoxin
[118]. These thiol-reactive antioxidants are also known to ap-
pear on the surface of cells [118, 119]. Therefore, it is to be
expected that these molecules also appear on the surface of
EVs either as membrane proteins or plasma proteins associat-
ing with the EVs. Indeed, peroxiredoxin 2 was present on the
surface of EVs [120, 121], and peroxiredoxin1 (Prdx1)-posi-
tive EVs were elevated in rheumatoid arthritis (RA) patient
plasma compared with healthy controls which may be a mark-
er of inflammation [115]. Since Prdx 1 is also present as a free
protein in plasma, it may be released together with EVs or it
associates with EVs after release, in the plasma. Protein disul-
fide isomerase is thought to be responsible for regulating cell
surface thiols [122] and associated with EV surface, and it also
seems to activate platelets [123].
Conclusions
The relatively large surface to volume ratio of EVs enables
highly efficient surface interactions of these structures with
cells and extracellular molecules. Such surface interactions
have outstanding importance since they determine the fate
of EVs by targeting them to the plasma membrane of cells
or to certain tissues. One of the most exciting aspects of
EV surface interactions is that they can be tailored by en-
gineering the EV-releasing cells [124, 125]. This way, by
having the designed EV-producing cells, one may achieve
to produce EVs with specific targeting molecules on their
surface and thus may be able to alter the biodistribution of
EVs used as drug delivery systems. Feasibility of this ap-
proach was first demonstrated when siRNA was success-
fully delivered to murine brain upon systemic administra-
tion of exosomes carrying a brain-targeting peptide [126].
This initial proof-of-concept study has been followed by
several subsequent works in which designer EVs were spe-
cifically targeted to tissues or cells [125]. The potential of
designing targeted EVs for drug delivery, and the known
ability of exosomes to cross blood tissue barriers such as
blood brain barrier, underlies the significance in emerging
EV-based therapies including gene therapy.
Another aspect of EV surface interactions is that due to
technical limitations, it is not feasible to perform comprehen-
sive analysis of EVs in situ in living tissues. Considering the
interactions of EVs both with cells and with molecules of the
microenvironment, there is an urgent need for much more
complex systems to model EV surface interactions.
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Recognizing the complexity of EV surface interactions, we
should change our way of thinking about EVs as Bpure^mem-
brane vesicles. We should rather consider EV surface interac-
tome in our experimental design since EV surface-associated
molecules can hinder those already present on the EV surface,
resulting in unexpected outcomes of both analysis and isola-
tion of EVs.
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